146 related articles for article (PubMed ID: 19569197)
1. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531).
Pullarkat VA; Gernsheimer TB; Wasser JS; Newland A; Guthrie TH; de Wolf JT; Stewart R; Berger D
Am J Hematol; 2009 Aug; 84(8):538-40. PubMed ID: 19569197
[No Abstract] [Full Text] [Related]
2. The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
Veneri D; Soligo L; Pizzolo G; Ambrosetti A
Blood Transfus; 2015 Oct; 13(4):694-5. PubMed ID: 26057496
[No Abstract] [Full Text] [Related]
3. Combination of romiplostim and rituximab: effective therapy of severe immune thrombocytopenia.
Pohlen M; Sargin B; Zicholl S; Bisping G; Müller-Tidow C; Berdel WE; Mesters R; Koschmieder S
Eur J Haematol; 2010 Apr; 84(4):362-4. PubMed ID: 20050881
[No Abstract] [Full Text] [Related]
4. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
[No Abstract] [Full Text] [Related]
5. Platelet production bolstered with romiplostim approval.
Morrow T
Manag Care; 2008 Oct; 17(10):49-50. PubMed ID: 18990926
[No Abstract] [Full Text] [Related]
6. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.
Newland A; Caulier MT; Kappers-Klunne M; Schipperus MR; Lefrere F; Zwaginga JJ; Christal J; Chen CF; Nichol JL
Br J Haematol; 2006 Nov; 135(4):547-53. PubMed ID: 17061981
[TBL] [Abstract][Full Text] [Related]
7. Emperipolesis in a patient receiving romiplostim.
Cooper N; Bain BJ
Am J Hematol; 2016 Jan; 91(1):166. PubMed ID: 26407183
[No Abstract] [Full Text] [Related]
8. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
Bussel JB; Kuter DJ; George JN; McMillan R; Aledort LM; Conklin GT; Lichtin AE; Lyons RM; Nieva J; Wasser JS; Wiznitzer I; Kelly R; Chen CF; Nichol JL
N Engl J Med; 2006 Oct; 355(16):1672-81. PubMed ID: 17050891
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
[TBL] [Abstract][Full Text] [Related]
10. [New therapeutic possibilities in chronic ITP in adults].
Jönsson S; Olsson B; Wadenvik H
Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1476-9. PubMed ID: 19579436
[No Abstract] [Full Text] [Related]
11. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.
Shirasugi Y; Ando K; Hashino S; Nagasawa T; Kurata Y; Kishimoto Y; Iwato K; Ohtsu T; Berger DP
Int J Hematol; 2009 Sep; 90(2):157-165. PubMed ID: 19543952
[TBL] [Abstract][Full Text] [Related]
12. AMG 531: an investigational thrombopoiesis-stimulating peptibody.
Nichol JL
Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):723-5. PubMed ID: 16933266
[TBL] [Abstract][Full Text] [Related]
13. Two new drugs for chronic ITP.
Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
[TBL] [Abstract][Full Text] [Related]
14. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
Nurden AT; Viallard JF; Nurden P
Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
[TBL] [Abstract][Full Text] [Related]
15. Pseudothrombocytopenia in a patient receiving romiplostim for immune thrombocytopenic purpura.
Fozza C; Pardini S; Marras T; Longu F; Isoni A; Contini S; Longinotti M
Ann Hematol; 2014 May; 93(5):899-900. PubMed ID: 24081576
[No Abstract] [Full Text] [Related]
16. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura.
Dultz G; Kronenberger B; Azizi A; Mihm U; Vogl TJ; Sarrazin U; Sarrazin C; Zeuzem S; Hofmann WP
J Hepatol; 2011 Jul; 55(1):229-32. PubMed ID: 21310200
[TBL] [Abstract][Full Text] [Related]
17. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Jamali F; Lemery S; Ayalew K; Robottom S; Robie-Suh K; Rieves D; Pazdur R
Oncology (Williston Park); 2009 Jul; 23(8):704-9. PubMed ID: 19711585
[TBL] [Abstract][Full Text] [Related]
18. A Case of Multiple Cerebral Infarction Preceding Acute Exacerbation of Idiopathic Thrombocytopenic Purpura.
Sasaki T; Yasuda T; Abe D; Miyano R; Kainaga M; Tomura N; Kitamura M; Nakayama T; Imafuku I
J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):789-791. PubMed ID: 30553647
[TBL] [Abstract][Full Text] [Related]
19. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Godeau B;
Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
[No Abstract] [Full Text] [Related]
20. Evolution of platelet function in adult patients with chronic immune thrombocytopenia on romiplostim treatment.
Ignatova AA; Demina IA; Ptushkin VV; Khaspekova SG; Shustova ON; Pankrashkina MM; Ryabykh AA; Obydennyi SI; Strelkova OS; Polokhov DM; Seregina EA; Poletaev AV; Ataullakhanov FI; Kireev II; Mazurov AV; Maschan AA; Novichkova GA; Panteleev MA
Br J Haematol; 2019 Oct; 187(2):e38-e42. PubMed ID: 31422582
[No Abstract] [Full Text] [Related]
[Next] [New Search]
